Noncovalent Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib and chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel have gained FDA approval for double-refractory chronic ...
Oral induction therapy with obefazimod (Abivax) for 8 weeks led to clinically meaningful improvements across all efficacy endpoints in a highly refractory population of patients with moderately to ...
Panelists discuss how emerging therapies like menin inhibitors show promise based on strong preclinical data and clinical responses, while CD47 inhibitors have faced setbacks in phase 3 trials, with ...
Please provide your email address to receive an email when new articles are posted on . Researchers reported an encouraging pathologic complete response rate with SHR-A1811 monotherapy. No ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Stephen M. Ansell, MD, PhD, discusses highlights in rare histologies, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results